Objective: To investigate the expression and clinical significance of serum Cripto-1 and Kim-1 in patients with renal cancer. Methods: A total of 108 kidney cancer patients from January 2017 to January 2019 were selected as the research objects (experimental group). During the same period, another 60 healthy volunteers (control group) were selected. Enzyme-linked immunosorbent assay was used to detect serum Cripto-1 and Kim-1 levels in the two groups. The differences in serum Cripto-1 and Kim-1 levels of patients with different tumor diameters, tumor stages, Fuhrman grade, with or without lymph node and distant metastasis of renal cell carcinoma were analyzed. Receiver operating characteristic (ROC) curve was drawn to analyze the predictive diagnostic value of serum Cripto-1 and Kim-1 in patients with renal cell carcinoma. Results: The serum Cripto-1 and Kim-1 levels of the experimental group were higher than those of the control group, respectively, and the difference was statistically significant (P<0.05). The postoperative serum Cripto-1 and Kim-1 levels of the experimental group were lower than those of preoperative, and the difference was statistically significant (P<0.05). The serum Cripto-1 and Kim-1 levels of renal cancer patients with different tumor diameter, tumor stage, Fuhrman grade, with or without lymph node and distant metastasis were compared with statistical significances (P<0.05). The ROC curve showed that Cripto-1 predicted the area under the curve for diagnosing kidney cancer at 0.795, and the sensitivity and specificity were 0.813 and 0.782, respectively. The area under the Kim-1 curve was 0.782, and the sensitivity and specificity were 0.786 and 0.753, respectively. The area under the Cripto-1+Kim-1 combined detection curve was 0.854, and the sensitivity and specificity were 0.896 and 0.824, respectively. Conclusion: Serum Cripto-1 and Kim-1 levels in patients with renal cell carcinoma are significantly increased. Serum Cripto-1 and Kim-1 is related to the tumor diameter, tumor stage, Fuhrman grade, with or without lymph node and distant metastasis of renal cancer. Combined detection of serum Cripto-1 and Kim-1 has high clinical value in the diagnosis of renal cell carcinoma.
 CAMPELL S,UZZO R G,ALLAF M E,et al.Renal mass and localized renal cancer:AUA guideline[J].J Urol,2017,198(3):520-529.
 NAGAPKA T,KARASAWA H,CASTRO N P,et al.An evolving web of signaling networks regulated by Cripto-l[J].Growth Factors,2012,30(1):13-21.
 LEORIK P S,LUIZ A B S,BRUNO T S,et al.Cripto-1 is overexpressed in carcinoma expleomorphic adenoma of salivary gland[J].Eur Arch Otorhinolaryngol,2018,275(6):1595-1600.
 KLAUZINSKA M,CASTRO N P,RANGEL M C,et al.The multifaceted role of the embryonic gene Cripto-1 in cancer,stem cells and epithelial-mesenchymal transition[J].Semin Cancer Biol,2014,29(13):51-58.
 LO R C,LEUNG C O,CHAN K K,et al.Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing dishevelled-3 and activating Wnt/β-catenin pathway[J].Cell Death Differ,2018,25(8):1426-1441.
 华丽,周燕红,游红霞.Cripto-1 siRNA联合5-FU对大肠癌细胞增殖和迁移的影响及与EMT的关系[J].山东医药,2019,17(59):16-19.
 LI X S,WANG J H,YANG X Z,et al.Beneficial effects of Cripto-1 for transarterial chemoembolization in hepatocellular carcinoma[J].Aging (Albany NY),2019,11(10):2998-3011.
 KUSHLINSKⅡ N E,GERSHTEIN E S,NABEREZHNOV D S,et al.Kidney injury molecule-1(KIM-1) in blood plasma of patients with clear-cell carcinoma[J].Bull Exp Biol Med,2019,167(3):388-392.
 XUE Y J,CHEN S N,CHEN E G,et al.Cripto-1 expression in patients with clear cell renal cell carcinoma is associated with poor disease outcome[J].J Exp Clin Cancer Res,2019,38(1):378-389.
 GHISLAINE S,DAVID C M,ELIO R,et al.KIM-1 as a blood-based marker for early detection of kidney cancer:a prospective nested case-control study[J].Clin Cancer Res,2018,24(22):5594-5601.